Cantor Fitzgerald Reiterates “Overweight” Rating for Zura Bio (NASDAQ:ZURA)

Cantor Fitzgerald restated their overweight rating on shares of Zura Bio (NASDAQ:ZURA) in a research note published on Wednesday morning,Benzinga reports.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Monday, November 18th. Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Piper Sandler restated an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a research report on Thursday, September 19th. Finally, Chardan Capital cut their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $2.28 on Wednesday. The firm has a 50 day moving average of $3.76 and a 200-day moving average of $3.80. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, equities research analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. acquired a new stake in Zura Bio during the second quarter worth approximately $8,446,000. Armistice Capital LLC grew its position in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares during the period. Braidwell LP bought a new stake in shares of Zura Bio in the 3rd quarter valued at $10,040,000. Great Point Partners LLC lifted its position in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares during the period. Finally, Forefront Analytics LLC grew its holdings in Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after purchasing an additional 7,531 shares during the period. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.